- Home
- WRBY
WRBY
Warby Parker Inc.
as 02-21-2025 1:45pm EST
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Upcoming Earnings Alert:
Get ready for potential market movements as Warby Parker Inc. WRBY prepares to release earnings report on 27 Feb 2025.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 3.1B | IPO Year: | 2021 |
| Target Price: | $22.25 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.35 - $28.68 | Next Earning Date: | 02-27-2025 |
| Revenue: | $742,527,000 | Revenue Growth: | 13.47% |
| Revenue Growth (this year): | 16.92% | Revenue Growth (next year): | 13.42% |
Stock Insider Trading Activity of Warby Parker Inc. (WRBY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blumenthal Neil Harris | WRBY | Co-Chief Executive Officer | Jan 30 '25 | Sell | $27.61 | 50,000 | $1,380,500.00 | 12,177 | |
| Gilboa David Abraham | WRBY | Co-Chief Executive Officer | Jan 2 '25 | Sell | $25.32 | 375,000 | $9,437,514.92 | 12,306 | |
| Blumenthal Neil Harris | WRBY | Co-Chief Executive Officer | Jan 2 '25 | Sell | $25.14 | 300,000 | $7,542,000.00 | 12,177 | |
| Gilboa David Abraham | WRBY | Co-Chief Executive Officer | Dec 20 '24 | Sell | $25.11 | 144,212 | $3,621,163.32 | 12,306 | |
| Blumenthal Neil Harris | WRBY | Co-Chief Executive Officer | Dec 20 '24 | Sell | $25.08 | 93,946 | $2,356,165.68 | 12,177 | |
| Gilboa David Abraham | WRBY | Co-Chief Executive Officer | Dec 18 '24 | Sell | $25.09 | 55,788 | $1,399,720.92 | 12,306 | |
| Blumenthal Neil Harris | WRBY | Co-Chief Executive Officer | Dec 18 '24 | Sell | $25.09 | 56,054 | $1,406,394.86 | 12,177 | |
| Miller Steven Clive | WRBY | Chief Financial Officer | Dec 11 '24 | Sell | $23.85 | 7,016 | $167,331.60 | 182,130 | |
| Gilboa David Abraham | WRBY | Co-Chief Executive Officer | Dec 10 '24 | Sell | $23.67 | 358,947 | $8,453,614.50 | 12,306 | |
| Blumenthal Neil Harris | WRBY | Co-Chief Executive Officer | Dec 9 '24 | Sell | $23.65 | 50,000 | $1,182,500.00 | 12,177 |
Latest Warby Parker Inc. News
WRBY Breaking Stock News: Dive into WRBY Ticker-Specific Updates for Smart Investing
StockStory
10 days ago
Q3 Rundown: Bath and Body Works (NYSE:BBWI) Vs Other Beauty and Cosmetics Retailer Stocks
Insider Monkey
14 days ago
Warby Parker Inc. (WRBY): Among The Footwear Apparel Stocks Affected By China Tariffs
StockStory
14 days ago
Beauty and Cosmetics Retailer Stocks Q3 Teardown: Warby Parker (NYSE:WRBY) Vs The Rest
Zacks
15 days ago
Kenvue (KVUE) Q4 Earnings Meet Estimates
Business Wire
15 days ago
Warby Parker to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
StockStory
16 days ago
1 Consumer Stock to Stash and 2 to Sell
MT Newswires
16 days ago
Warby Parker Shares Slightly Lower After Citigroup Downgrade
Investing.com
16 days ago
Warby Parker stock rating cut to sell by Citi on valuation concerns
Compare WRBY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "WRBY Warby Parker Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.